Get the Stockscreener App
6.08
9.75%
0.54
After Hours:
6.22
0.14
+2.30%
Phathom Pharmaceuticals Inc Stock (PHAT) Forecast
The Phathom Pharmaceuticals Inc (PHAT) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $23.09, representing a +279.73% increase from the current price of $6.08. The highest analyst price target is $27.10, and the lowest is $19.07.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PHAT Price Target
Average 28.67
(+371.56% Upside)
Is Phathom Pharmaceuticals Inc (PHAT) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 56.03 | Neutral |
| STOCH(9,6) | 35.25 | Neutral |
| STOCHRSI(14) | 100.00 | Sell |
| MACD(12,26) | -0.2415 | Buy |
| ADX(14) | 20.05 | Neutral |
| William %R | -30.93 | Neutral |
| CCI(14) | 91.93 | Neutral |
Buy: 1
Sell: 1
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
5.024
Buy
|
5.2153
Buy
|
| MA20 |
5.3155
Buy
|
5.3345
Buy
|
| MA50 |
5.9558
Buy
|
6.2299
Sell
|
| MA100 |
8.4531
Sell
|
7.9202
Sell
|
| MA200 |
11.07
Sell
|
9.2572
Sell
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, PHAT could be considered a Neutral, with 17 technical analysis indicators signaling 6 Buy signals, 6 signaling Sell signals and 5 Neutral signals. This suggests that investors should exercise caution when entering new positions on PHAT, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 56.03 indicates that PHAT is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 35.25 indicates that PHAT is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 100 indicates that PHAT is oversold. This suggests that PHAT price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 20.05 suggests that there may be some movement in price, but it lacks strength or conviction.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 91.93 indicates that PHAT is still overbought but not to an extreme extent.
Long-term PHAT price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Phathom Pharmaceuticals Inc financial reports and earnings history, Phathom Pharmaceuticals Inc (PHAT) stock could reach $12.37 by 2030, $24.30 by 2040 and $67.44 by 2050. See the projected annual prices until 2050 of the Phathom Pharmaceuticals Inc stock below:
- Phathom Pharmaceuticals Inc (PHAT) is expected to reach an average price of $18.80 in 2035, with a high prediction of $14.60 and a low estimate of $11.11. This indicates an $209.21% rise from the last recorded price of $6.08.
- Phathom Pharmaceuticals Inc (PHAT) stock is projected to chart a bullish course in 2040, with an average price target of $25.71, representing an $322.79% surge from its current level. The forecast ranges from a conservative $24.12 to a sky-high $24.30.
- Our analysts predict Phathom Pharmaceuticals Inc (PHAT) to jump 750.06% by 2045, soaring from $51.75 to an average price of $51.68, potentially reaching $50.20. While $51.75 is the low estimate, the potential upside is significant.
- Phathom Pharmaceuticals Inc (PHAT) stock is expected to climb by 2050, reaching an average of $67.83, a $1,016% jump from its current level. However, a wide range of estimates exists, with high and low targets of $67.44 and $20.09, respectively, highlighting the market's uncertainty.
Phathom Pharmaceuticals Inc Stock (PHAT) Year by Year Forecast
Phathom Pharmaceuticals Inc Stock (PHAT) Price Forecast for 2025
Phathom Pharmaceuticals Inc Stock (PHAT) is expected to reach an average price of $32.43 in 2025, with a high prediction of $50.52 and a low estimate of $14.33. This indicates an +433.35% rise from the last recorded price of $6.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| April, 2025 | $21.23 | $19.07 | $27.10 | +249.18% |
| May, 2025 | $23.29 | $19.05 | $24.87 | +283.11% |
| June, 2025 | $26.57 | $21.20 | $27.79 | +336.94% |
| July, 2025 | $30.07 | $21.81 | $30.87 | +394.64% |
| August, 2025 | $25.11 | $24.80 | $37.87 | +312.95% |
| September, 2025 | $24.78 | $19.68 | $26.12 | +307.56% |
| October, 2025 | $35.29 | $24.62 | $35.76 | +480.40% |
| November, 2025 | $31.01 | $27.64 | $38.30 | +410.05% |
| December, 2025 | $24.85 | $21.81 | $32.76 | +308.79% |
Phathom Pharmaceuticals Inc Stock (PHAT) Price Forecast for 2026
The predicted value for Phathom Pharmaceuticals Inc (PHAT) in 2026 is set at an average of $16.02. Estimates vary from a peak of $28.70 to a trough of $3.3401, indicating an +163.50% surge from the present price of $6.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $21.14 | $19.57 | $28.70 | +247.74% |
| February, 2026 | $22.73 | $19.21 | $26.93 | +273.77% |
| March, 2026 | $22.82 | $20.84 | $24.58 | +275.29% |
| April, 2026 | $22.03 | $18.77 | $23.51 | +262.28% |
| May, 2026 | $24.07 | $18.20 | $24.26 | +295.87% |
| June, 2026 | $20.49 | $19.95 | $25.68 | +237.04% |
| July, 2026 | $18.00 | $14.80 | $23.12 | +196.06% |
| August, 2026 | $9.0231 | $8.8431 | $20.37 | +48.41% |
| September, 2026 | $8.2316 | $6.4652 | $9.9688 | +35.39% |
| October, 2026 | $4.4244 | $3.4294 | $9.5287 | -27.23% |
| November, 2026 | $5.8271 | $3.3401 | $7.2371 | -4.16% |
| December, 2026 | $6.9556 | $5.3428 | $9.4285 | +14.40% |
Phathom Pharmaceuticals Inc Stock (PHAT) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Phathom Pharmaceuticals Inc (PHAT) is $3.5399, with a high forecast of $7.0613 and a low forecast of $0.0185. This indicates an -41.78% decrease from the last price of $6.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $3.3384 | $0.987 | $7.0613 | -45.09% |
| February, 2027 | $3.4712 | $3.1612 | $5.8662 | -42.91% |
| March, 2027 | $2.5104 | $1.3725 | $4.7825 | -58.71% |
| April, 2027 | $3.5376 | $2.8247 | $3.0029 | -41.82% |
| May, 2027 | $0.5952 | $0.7648 | $1.3452 | -90.21% |
| June, 2027 | $1.1536 | $0.4635 | $1.2136 | -81.03% |
| July, 2027 | $0.7436 | $0.5493 | $3.3593 | -87.77% |
| August, 2027 | $1.8792 | $0.0185 | $3.1192 | -69.09% |
| September, 2027 | $1.5776 | $0.5006 | $2.6719 | -74.05% |
| October, 2027 | $0.6504 | $0.079 | $2.2783 | -89.30% |
| November, 2027 | $2.0532 | $0.1961 | $2.8732 | -66.23% |
| December, 2027 | $0.0516 | $0.6534 | $3.9402 | -99.15% |
Phathom Pharmaceuticals Inc Stock (PHAT) Price Forecast for 2028
In 2028, Phathom Pharmaceuticals Inc (PHAT) is projected to reach an average price of $4.8266, with a high projection of $9.638 and a low estimate of $0.0151. This indicates an -20.62% fall from the last price of $6.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $0.2856 | $0.4227 | $4.9173 | -95.30% |
| February, 2028 | $0.4572 | $0.1678 | $1.8215 | -92.48% |
| March, 2028 | $0.3944 | $1.0944 | $1.4657 | -93.51% |
| April, 2028 | $4.3984 | $0.6584 | $4.6084 | -27.66% |
| May, 2028 | $3.8869 | $3.3241 | $6.5311 | -36.07% |
| June, 2028 | $6.6896 | $3.7426 | $7.3596 | +10.03% |
| July, 2028 | $7.3224 | $5.4224 | $8.0435 | +20.43% |
| August, 2028 | $7.1209 | $6.4638 | $9.638 | +17.12% |
| September, 2028 | $5.9337 | $5.448 | $7.5666 | -2.41% |
| October, 2028 | $3.0664 | $2.4664 | $6.5693 | -49.57% |
| November, 2028 | $0.6649 | $0.0151 | $3.4021 | -89.06% |
| December, 2028 | $0.5977 | $0.132 | $0.9366 | -90.17% |
Phathom Pharmaceuticals Inc Stock (PHAT) Price Forecast for 2029
The 2029 price forecast for Phathom Pharmaceuticals Inc Stock (PHAT) is $8.9525 on average, with a high prediction of $17.87 and a low estimate of $0.0332. This represents an +47.25% increase from the previous price of $6.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $2.2561 | $0.6834 | $3.0661 | -62.89% |
| February, 2029 | $0.3189 | $0.0332 | $2.5618 | -94.75% |
| March, 2029 | $4.3617 | $0.0746 | $5.1917 | -28.26% |
| April, 2029 | $2.3944 | $1.4544 | $4.9874 | -60.62% |
| May, 2029 | $3.0529 | $2.0601 | $6.3172 | -49.79% |
| June, 2029 | $6.08 | $2.8586 | $6.08 | +0.00% |
| July, 2029 | $4.5245 | $5.3845 | $5.5472 | -25.58% |
| August, 2029 | $6.6275 | $6.4803 | $5.1475 | +9.01% |
| September, 2029 | $1.518 | $0.152 | $17.87 | -75.03% |
| October, 2029 | $4.1049 | $0.6606 | $9.6902 | -32.48% |
| November, 2029 | $2.1505 | $0.4885 | $15.14 | -64.63% |
| December, 2029 | $1.276 | $4.324 | $2.7754 | -79.01% |
Phathom Pharmaceuticals Inc Stock (PHAT) Price Forecast for 2030
Phathom Pharmaceuticals Inc Stock (PHAT) is expected to reach an average price of $18.52 in 2030, with a high forecast of $36.50 and a low forecast of $0.5296. This signifies an +204.53% surge from the last price of $6.08.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $3.033 | $0.6712 | $12.37 | -50.12% |
| February, 2030 | $14.10 | $1.7843 | $19.54 | +131.88% |
| March, 2030 | $7.534 | $7.244 | $36.50 | +23.92% |
| April, 2030 | $2.0696 | $0.5296 | $8.2854 | -65.96% |
| May, 2030 | $12.55 | $2.371 | $13.48 | +106.36% |
| June, 2030 | $7.6821 | $5.552 | $13.14 | +26.35% |
| July, 2030 | $12.76 | $6.7748 | $14.49 | +109.85% |
| August, 2030 | $15.40 | $8.6495 | $17.12 | +153.36% |
| September, 2030 | $16.63 | $10.55 | $17.77 | +173.52% |
| October, 2030 | $7.627 | $7.062 | $24.95 | +25.44% |
| November, 2030 | $13.10 | $6.8784 | $15.20 | +115.50% |
| December, 2030 | $18.94 | $11.95 | $23.17 | +211.48% |
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):